DRW Securities’s Soleno Therapeutics SLNO Stock Holding History

DRW Securities’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,761	Closed	-$1.05M	–	1243
2025 Q1	$1.05M	Buy	+14,761	New	+$719K	0.03%	261

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DRW Securities's SLNO Position: Q2 2025 in Review

DRW Securities sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 14,761 shares — an estimated $1.05M sold.

DRW Securities first reported a position in SLNO in Q1 2025 and held it in 1 quarter. The position peaked at $1.05M in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

DRW Securities reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
DRW Securities sold 14,761 Soleno Therapeutics shares in Q2 2025, an estimated $1.05M.
DRW Securities first reported a position in Soleno Therapeutics in Q1 2025 and held it in 1 quarter.
DRW Securities's Soleno Therapeutics position peaked at $1.05M in Q1 2025.
233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on DRW Securities's 13F filing for Q2 2025, filed 14 Aug 2025.